Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi-Led Continuous Manufacturing JV Now Up and Running
April 4, 2022
- 400 Kobayashi Kako Staffers Move to Trust Pharmatech
April 4, 2022
- Ukraine War Disrupts Ryzodeg Supplies to Japan: Novo
April 4, 2022
- Sumitomo Dainippon Renamed “Sumitomo Pharma”
April 4, 2022
- COVID-19 as Catalyst for Introducing Decentralized Clinical Trials in Japan; Some Results Due Out by Year-End
April 1, 2022
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat Nixed in US
April 1, 2022
- Asahi Kasei Grabs Japan Rights to VectivBio’s GLP-2 Analog Peptide
April 1, 2022
- Kobayashi Kako Manufacturing Unit Now Under Sawai; 170 Staffers Remain for Compensation, Drug Handover
April 1, 2022
- Daiichi Sankyo to Offload Cravit Business in China to Local Firm
April 1, 2022
- Sumitomo Dainippon Kicks Off PI/II Study for AML Drug
April 1, 2022
- Ono Bags Global Rights to Numab’s Multispecific I/O Antibody
April 1, 2022
- Healios’ Cell Processing Center in Kobe to Begin Full Operations in Mid-2022
March 31, 2022
- Sandoz to Exclusively Sell Nichi-Iko’s Avastin Biosimilar in Japan
March 31, 2022
- Sumitomo Dainippon to Set Up Holding Firm in China
March 31, 2022
- Pfizer Files Precedex for New Pediatric Indication as “Specific Use Drug”
March 31, 2022
- Ono Collaborates with French Startup in AI-Based Drug Discovery
March 31, 2022
- Kyorin Ties Up with US Biotech for Drug Discovery Research Using Protein Engineering
March 31, 2022
- Taiho’s Biliary Cancer Med Gets US FDA’s Priority Review
March 31, 2022
- Ube, iPSC Startup to Develop IPF Drug, Eyes Clinical Trial in FY2023
March 30, 2022
- MSD Says to Ensure HPV Vaccine Supply in Japan, 4 Million-Plus Syringes for FY2022
March 30, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…